相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors
Valerio Leoni et al.
JOURNAL OF VIROLOGY (2018)
Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells
Biljana Petrovic et al.
JOURNAL OF VIROLOGY (2018)
Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle
Christiane Dinsart et al.
HUMAN GENE THERAPY (2017)
A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells
Valerio Leoni et al.
JOURNAL OF VIROLOGY (2017)
Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins
Biljana Petrovic et al.
PLOS PATHOGENS (2017)
How to develop viruses into anticancer weapons
Roberto Cattaneo et al.
PLOS PATHOGENS (2017)
Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation
Ruta Veinalde et al.
ONCOIMMUNOLOGY (2017)
TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma
Brian Hutzen et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Immune System, Friend or Foe of Oncolytic Virotherapy?
Anna C. Finley et al.
FRONTIERS IN ONCOLOGY (2017)
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Omid Hamid et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Local Delivery of OncoVEXmGM-CSF Generates Systemic AntitumorImmuneResponses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade
Achim K. Moesta et al.
CLINICAL CANCER RESEARCH (2017)
The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells
Jun-Feng Ye et al.
CELLULAR IMMUNOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility
P-Y Wang et al.
GENE THERAPY (2016)
Oncolytic viruses-immunotherapeutics on the rise
Brian A. Keller et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses
Kevin A. Cassady et al.
VIRUSES-BASEL (2016)
Retargeting Strategies for Oncolytic Herpes Simplex Viruses
Gabriella Campadelli-Fiume et al.
VIRUSES-BASEL (2016)
IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice
Eric D. Thomas et al.
JOURNAL OF OVARIAN RESEARCH (2016)
Noninvasive Monitoring of Glioma Growth in the Mouse
Francesco Alessandrini et al.
JOURNAL OF CANCER (2016)
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
Daxa M. Patel et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2016)
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
Barbara Banelli et al.
CELL CYCLE (2015)
Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells
Eleni Anastasiadou et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV
Lucia Mazzacurati et al.
MOLECULAR THERAPY (2015)
Cancer-fighting viruses win approval
Heidi Ledford
NATURE (2015)
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
Valerio Leoni et al.
ONCOTARGET (2015)
The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors
Valentina Gatta et al.
PLOS PATHOGENS (2015)
New viruses for cancer therapy: meeting clinical needs
Tanner S. Miest et al.
NATURE REVIEWS MICROBIOLOGY (2014)
Oncolytic viruses as therapeutic cancer vaccines
David L. Bartlett et al.
MOLECULAR CANCER (2013)
Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus
Hiroaki Uchida et al.
MOLECULAR THERAPY (2013)
Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1
David C. Gaston et al.
PLOS ONE (2013)
Viral therapy of glioblastoma multiforme
Richard J. Whitley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
Patrizia Nanni et al.
PLOS PATHOGENS (2013)
Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models
Wei Zhang et al.
NEOPLASIA (2013)
Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice
E. Reisoli et al.
CANCER GENE THERAPY (2012)
Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity
Nina Gottschalk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Replication-competent Herpes Simplex Virus Retargeted to HER2 as Therapy for High-grade Glioma
Eleonora Gambini et al.
MOLECULAR THERAPY (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
Preclinical Evaluation of Oncolytic Δγ134.5 Herpes Simplex Virus Expressing Interleukin-12 for Therapy of Breast Cancer Brain Metastases
James J. Cody et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2012)
Single cell detection of latent cytomegalovirus reactivation in host tissue
Anja Marquardt et al.
JOURNAL OF GENERAL VIROLOGY (2011)
Rethinking herpes simplex virus: the way to oncolytic agents
Gabriella Campadelli-Fiume et al.
REVIEWS IN MEDICAL VIROLOGY (2011)
Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
Kevin J. Harrington et al.
CLINICAL CANCER RESEARCH (2010)
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
Howard L. Kaufman et al.
FUTURE ONCOLOGY (2010)
Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver
Sunil K. Geevarghese et al.
HUMAN GENE THERAPY (2010)
A Double Mutation in Glycoprotein gB Compensates for Ineffective gD-Dependent Initiation of Herpes Simplex Virus Type 1 Infection
Hiroaki Uchida et al.
JOURNAL OF VIROLOGY (2010)
Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL
Jing-Hua Huang et al.
MOLECULAR THERAPY (2010)
Transcriptional and Translational Dual-regulated Oncolytic Herpes Simplex Virus Type 1 for Targeting Prostate Tumors
Cleo Y. F. Lee et al.
MOLECULAR THERAPY (2010)
Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand
Hong Sung Kim et al.
CANCER RESEARCH (2009)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery
Jessica Kao et al.
PLOS ONE (2009)
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells
Laura Menotti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2
Laura Menotti et al.
JOURNAL OF VIROLOGY (2008)
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Roberto Cattaneo et al.
NATURE REVIEWS MICROBIOLOGY (2008)
Construction and characterization of a herpes simplex virus type I recombinant expressing green fluorescent protein: Acute phase replication and reactivation in mice
John W. Balliet et al.
VIROLOGY (2007)
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver
Nancy Kemeny et al.
HUMAN GENE THERAPY (2006)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS
William W. Gierasch et al.
JOURNAL OF VIROLOGICAL METHODS (2006)
A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors
Laura Menotti et al.
JOURNAL OF VIROLOGY (2006)
Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13α2 receptor
GY Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor
H Kamiyama et al.
GENE THERAPY (2006)
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model
EK Hellums et al.
NEURO-ONCOLOGY (2005)
Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Rα2 receptor of malignant glioma cells
GY Zhou et al.
JOURNAL OF VIROLOGY (2005)
Rescue and propagation of fully retargeted oncolytic measles viruses
T Nakamura et al.
NATURE BIOTECHNOLOGY (2005)
Simple and highly efficient BAC recombineering using gaIK selection
S Warming et al.
NUCLEIC ACIDS RESEARCH (2005)
The herpes simplex virus JMP mutant enters receptor-negative J cells through a novel pathway independent of the known receptors nectin1, HveA, and nectin2
F Cocchi et al.
JOURNAL OF VIROLOGY (2004)
Interleukin-12 and the regulation of innate resistance and adaptive immunity
G Trinchieri
NATURE REVIEWS IMMUNOLOGY (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: Viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo
M Tanaka et al.
JOURNAL OF VIROLOGY (2003)
The type III epidermal growth factor receptor mutation - Biological significance and potential target for anti-cancer therapy
MW Pedersen et al.
ANNALS OF ONCOLOGY (2001)
Glycoprotein D or J delivered in trans blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins
GY Zhou et al.
JOURNAL OF VIROLOGY (2000)
Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe
IAJ Lorimer et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
分享论文
